1. L’arrivée de l’immunothérapie dans le lymphome de Hodgkin.
- Author
-
Gilardin L, Amorim S, Bernard S, Ravdan O, Thieblemont C, and Brice P
- Subjects
- Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents, Immunological adverse effects, Antineoplastic Agents, Immunological therapeutic use, B7-H1 Antigen metabolism, Brentuximab Vedotin, Clinical Trials as Topic, Hodgkin Disease pathology, Humans, Immunoconjugates therapeutic use, Nivolumab adverse effects, Nivolumab therapeutic use, Programmed Cell Death 1 Receptor metabolism, Recurrence, Reed-Sternberg Cells, Tumor Microenvironment, B7-H1 Antigen antagonists & inhibitors, Hodgkin Disease therapy, Immunotherapy, Programmed Cell Death 1 Receptor antagonists & inhibitors
- Abstract
Immunotherapy of Hodgkin Lymphoma: Classical Hodgkin lymphoma (HL) is a rare hematological cancer, affecting preferentially young adults. Using a risk-adapted approach, HL has become highly curable (>80%) with front-line chemotherapy in addition with radiotherapy, despite long term significant toxicity. Some patients are primary refractory or relapse after first-line chemotherapy, requiring high dose chemotherapy with serious side effects. Studies of the microenvironment from HL tissue reveal ineffective inflammatory and immune cell infiltrate surrounding Reed-Sternberg cells, involving the Programmed cell Death 1 (PD-1)/PD-ligand-1 checkpoint pathways. Recently, immune checkpoint inhibitors demonstrated high efficacy for relapsed and refractory patients, with a favorable safety profile but indeterminate long term outcome. Guidelines for nivolumab or pembrolizumab treatment in HL remain to be established., (© 2018 Société Française du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés.)
- Published
- 2018
- Full Text
- View/download PDF